Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Short term Debt (2020 - 2021)

Tg Therapeutics has reported Short term Debt over the past 2 years, most recently at $975000.0 for Q4 2021.

  • Quarterly results put Short term Debt at $975000.0 for Q4 2021, down 95.6% from a year ago — trailing twelve months through Dec 2021 was $975000.0 (down 95.6% YoY), and the annual figure for FY2021 was $975000.0, down 95.6%.
  • Short term Debt for Q4 2021 was $975000.0 at Tg Therapeutics, down from $16.0 million in the prior quarter.
  • Over the last five years, Short term Debt for TGTX hit a ceiling of $30.1 million in Q1 2021 and a floor of $975000.0 in Q4 2021.